共 50 条
- [1] MIRIKIZUMAB PHARMACOKINETICS AND EXPOSURE-RESPONSE IN PEDIATRIC PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 SHINE-1 STUDYGASTROENTEROLOGY, 2024, 166 (05) : S822 - S823Otani, YukiChua, LaiyiKomocsar, WendyLarkin, Amy E.Zhang, Xin
- [2] EFFICACY AND SAFETY OF MIRIKIZUMAB THERAPY IN PEDIATRIC PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: FINAL RESULTS FROM THE PHASE 2 SHINE-1 STUDYGASTROENTEROLOGY, 2024, 166 (05) : S819 - S820Kaplan, JessBousvaros, AthosTurner, DanDubinsky, Marla C.Komocsar, WendyLarkin, Amy E.Johns, JordanZhang, XinCrandall, WallaceArora, VipinTodd, KrisHyams, Jeffrey S.
- [3] Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active ulcerative colitis: Results from the Phase 3 LUCENT-1 studyJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 132 - 133Andrews, J. M.D'Haens, G.Kobayashi, T.Morris, N.Lissoos, T.Hoover, A.Li, X.Arora, V.Milch, C.Sandborn, W. J.Sands, B. E.
- [4] Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active Ulcerative Colitis: Results from the Phase 3 LUCENT-1 studyJOURNAL OF CROHNS & COLITIS, 2022, 16 : I028 - I029D'Haens, G.Kobayashi, T.Morris, N.Lissoos, T.Hoover, A.Li, X.Arora, V.Milch, C.Sandborn, W. J.Sands, B. E.
- [5] EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-1 STUDYGASTROENTEROLOGY, 2022, 162 (07) : S214 - S214D'Haens, GeertKobayashi, TakuMorris, NathanLissoos, TrevorHoover, AmyLi, XingyuanArora, VipinMilch, CatherineSandborn, William J.Sands, Bruce E.
- [6] EFFICACY AND SAFETY OF MIRIKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-2 STUDYGASTROENTEROLOGY, 2022, 162 (07) : S1393 - S1394Dubinsky, Marla C.Irving, Peter M.Li, XingyuanHowaldt, StefaniePokrotnieks, JurisKrueger, Kathryn A.Laskowski, JanelleLissoos, TrevorMilata, JoeMorris, NathanArora, VipinMilch, CatherineSands, Bruce E.
- [7] Efficacy and safety of mirikizumab as maintenance therapy in patients with moderately to severely active ulcerative colitis: Results from the Phase 3 LUCENT-2 studyJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 133 - 133Begun, J.Dubinsky, M. C.Irving, P. M.Li, X.Howaldt, S.Pokrotnieks, J.Krueger, K.Laskowski, J.Lissoos, T.Milata, J.Morris, N.Arora, V.Milch, C.Sands, B. E.
- [8] Extended induction treatment with mirikizumab in patients with moderately to severely active ulcerative colitis: results from a Phase 2 trialJOURNAL OF CROHNS & COLITIS, 2019, 13 : S54 - S54Sandborn, W. J.Ferrante, M.Bhandari, B. R.Berliba, E.Hibi, T.D'Haens, G. Geert R.Tuttle, J.Krueger, K.Friedrich, S.Durante, M.Arora, V.Feagan, B.
- [9] THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDYGASTROENTEROLOGY, 2023, 164 (06) : S1572 - S1572Allegretti, Jessica R.Peyrin-Biroulet, LaurentFeagan, Brian G.Bressler, BrianLichtenstein, Gary R.Huang, Kuan-Hsiang G.Germinaro, MatthewShipitofsky, NicoleJiang, LingjingZhang, HongyanHisamatsu, TadakazuPanes, JulianDignass, AxelSands, Bruce E.Rubin, David T.
- [10] EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDYGASTROENTEROLOGY, 2021, 160 (06) : S125 - S125Feagan, Brian G.Loftus, Edward V.Danese, SilvioVermeire, SeverineSandborn, William J.Ritter, Timothy E.Mehta, RajivSeidler, UrsulaSeibold, FrankBeales, IanKim, Hyo JongMcNally, JohnYun, ChoheeZhao, SallyLiu, XiaopengTasset, Chantal T.Besuyen, RobinWatanabe, MamoruSchreiber, StefanRogler, GerhardHibi, ToshifumiPeyrin-Biroulet, Laurent